Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RB2010
- Development stage
- Preclinical
- Lead developer
- Alveolus Bio
- Modality
- Cell Therapies
- Administration
- Inhalation
01
Overview
RB2010 is an inhaled, allogeneic, bone marrow-derived mesenchymal stem cell (MSC) therapy being developed by Alveolus Biomedical for the treatment of Idiopathic Pulmonary Fibrosis (IPF). The therapy is designed to be delivered directly to the lungs via inhalation, allowing the MSCs to localize in the alveolar regions where they can exert immunomodulatory, anti-inflammatory, and anti-fibrotic effects. This approach aims to address the underlying pathology of IPF by promoting tissue repair and reducing the progressive scarring characteristic of the disease. RB2010 is currently in the preclinical stage of development and is part of Alveolus Biomedical's broader platform of inhaled cell-based therapeutics.
Beyond the preview
Go deeper on RB2010.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RB2010.